AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...

Meanwhile, shares of Anaptysbio Inc. (NASDAQ:ANAB) were trading down 33% on news that its BTLA agonist, ANB-032, failed to meet any endpoints in the 201-patient Arise-AD trial. Loud and clear: Sound ...

Its most advanced project is MB272, an agonist of B- and T-lymphocyte attenuator (BTLA) which recently started phase 1 testing, and it has a PD-1 agonist called MB151 in late preclinical development.

Months Before C.E.O.’s Killing, the Suspect Went Silent. Where Was He? New details are emerging about Luigi Mangione’s growing impatience with “a capitalist society” and his search for ...

The Israeli prime minister said its forces would remain in Syrian territory until “a new force” filled the vacuum. Secretary of State Antony J. Blinken was in Jordan for talks on the aftermath ...